How do you choose a neoadjuvant therapy regimen for a patient with a triple negative breast cancer and a synchronous ER-/Her2+ breast cancer?
Answer from: Medical Oncologist at Academic Institution
Assuming there is no contraindication to administration of an anthracycline, I would favor weekly paclitaxel and weekly carboplatin with every 3 week trastuzumab and pertuzumab x 12 weeks followed by ddAC x 4. This gives the TNBC the benefit of the higher pCR rate seen with the addition of carboplat...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In these cases I would treat the patient using AC-THP if her cardiac status would allow it. This would give you coverage for both the TNBC and HER2+ tumors.
Comments
Medical Oncologist at Bayhealth Medical Center
why don't use TCHP? and do you use and BB or ACEi ...
why don't use TCHP? and do you use and BB or ACEi ...
Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
I use TCHP pretty regularly for HER2+ tumors, but ...
I use TCHP pretty regularly for HER2+ tumors, but ...
Medical Oncologist at UCSF Medical Center
I agree that this is a reasonable approach. Howeve...
I agree that this is a reasonable approach. Howeve...
Answer from: Medical Oncologist at Community Practice
@William M. Sikov's approach is very reasonable and one that I have attempted myself especially when the triple negative component is node positive. The same discussion applies with weakly or heterogeneously positive her2 fish and the patient has node positive disease.
However there are some ...
Comments
Medical Oncologist at Warren Alpert Medical School of Brown University
If you need a reference for the weekly paclitaxel,...
If you need a reference for the weekly paclitaxel,...
Medical Oncologist at Florida Cancer Specialists and Research Institute
Thank you @William M. Sikov, that will be immensel...
Thank you @William M. Sikov, that will be immensel...